State Street Corp raised its stake in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 5.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,081,871 shares of the company's stock after acquiring an additional 52,972 shares during the period. State Street Corp owned approximately 2.58% of SI-BONE worth $15,125,000 at the end of the most recent quarter.
Other institutional investors have also recently modified their holdings of the company. FMR LLC raised its stake in SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company's stock valued at $33,000 after purchasing an additional 1,198 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of SI-BONE during the 2nd quarter worth approximately $61,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of SI-BONE by 24.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company's stock worth $138,000 after acquiring an additional 2,108 shares in the last quarter. Arizona State Retirement System increased its stake in shares of SI-BONE by 9.0% in the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company's stock valued at $141,000 after purchasing an additional 903 shares during the last quarter. Finally, Walleye Capital LLC acquired a new position in SI-BONE during the third quarter worth about $144,000. 98.11% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In related news, CEO Laura Francis sold 10,048 shares of SI-BONE stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.58, for a total transaction of $126,403.84. Following the transaction, the chief executive officer now owns 482,875 shares of the company's stock, valued at $6,074,567.50. The trade was a 2.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Anthony J. Recupero sold 3,937 shares of the firm's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.60, for a total transaction of $49,606.20. Following the transaction, the insider now directly owns 228,554 shares in the company, valued at $2,879,780.40. The trade was a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,679 shares of company stock valued at $276,439 over the last 90 days. Company insiders own 3.90% of the company's stock.
SI-BONE Trading Up 0.8 %
SIBN stock traded up $0.11 during trading on Wednesday, hitting $13.27. The company had a trading volume of 56,657 shares, compared to its average volume of 381,453. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The business has a 50-day moving average of $13.43 and a 200-day moving average of $14.08. SI-BONE, Inc. has a one year low of $11.70 and a one year high of $21.70. The stock has a market cap of $556.52 million, a PE ratio of -14.42 and a beta of 1.20.
Analyst Ratings Changes
A number of brokerages have recently commented on SIBN. Needham & Company LLC reiterated a "buy" rating and issued a $19.00 price target on shares of SI-BONE in a research note on Wednesday, November 20th. Truist Financial increased their target price on SI-BONE from $16.00 to $18.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $23.00.
Read Our Latest Stock Report on SI-BONE
SI-BONE Company Profile
(
Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
Featured Articles
Before you consider SI-BONE, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SI-BONE wasn't on the list.
While SI-BONE currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
